Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The answer from PTSC to the USPTO contingency is .....

That is big news. No offense to Steve but too big an issue, imo, not to get a second confirmation. Knowing your strong position on this matter, it would go a long way if you were the one to 2nd it. Not being a wise guy here.

Fut has, previously, touched on the still tallying theory as well and I always give a lot of weight to "our accountant types", Fut, Bush, Vert in these matters.

Your question to Vert was good, imo, as the lifting of the trading ban has been a sticking point for me. Managent would have to remain as "ignorant" as us, but they have bought for themselves and the company which sends a different message,imo.

DD's post seems to ignore that to get to over 45 licensees, the J's need to be included, presently anyway. Were they not "officially" a licensee at the time of the 10Q? Did the revenues possibly then reflect the Feb. licensees and zero from the J's as we await the tallying? Where and when would a change in REV. Recoq. come into play? Still, wouldn't management have to remain "ignorant" in this senario as well? joe

Share
New Message
Please login to post a reply